TNK in Acute Ischemic Stroke [SPOTRIAS]

Completed

Phase N/A Results

Results

In the 3 lowest dosage tiers (0.1, 0.2, 0.4 mg/kg) of 25 patients each, there were no symptomatic and 2 (8%), 8 (32%), and 7 (28%) asymptomatic ICHs. The study was terminated at the 0.5 mg/kg tier after 2 of 13 patients (15%) had symptomatic and 3 (23%) had asymptomatic ICHs. Clinical outcome at 3 months was similar to control data from other thrombolytic trials.